Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
March 11, 2025 06:45 ET
|
Arvinas Inc.
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – –...
Arvinas to Participate in Upcoming Investor Conferences
March 04, 2025 16:05 ET
|
Arvinas Inc.
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
February 27, 2025 07:00 ET
|
Kymera Therapeutics, Inc.
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in...
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
February 26, 2025 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27
February 20, 2025 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 11, 2025 07:00 ET
|
Arvinas Inc.
– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in...
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
February 03, 2025 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
January 30, 2025 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
January 13, 2025 07:00 ET
|
Nurix Therapeutics, Inc.
Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 in additional...
Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer
January 13, 2025 07:00 ET
|
Amphista Therapeutics
Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer Appointment supports the Company’s ambitions to advance its portfolio of next generation Targeted Glue™ protein degrader...